

GAIASO appoints Dr Tracey Brown as new Chief Executive Officer

Melbourne, 16 September 2025 – GAIASO is pleased to announce the appointment of **Dr Tracey Brown** as its new Chief Executive Officer. A highly regarded biotech entrepreneur, Dr Brown is recognised for transforming breakthrough science into real-world products, with a track record of clear strategy, collaborative leadership, and disciplined execution in resource-constrained, high-growth settings. Her appointment strengthens GAIASO's mission to advance next-generation precision radiopharmaceuticals and deliver meaningful impact for patients.

Dr Brown brings **extensive international experience** across oncology and radiopharmaceutical development. She has held senior leadership roles at **Telix Pharmaceuticals**, **Anatara Lifesciences** and **Alchemia**, where she drove product development. Earlier, she co-founded **Meditech Research**, inventing the pioneering HyACT oncology drug-delivery platform and building a substantial patent estate while leading the portfolio strategy. She began her career at **Monash University**, where she led the Hyaluronan Laboratory and held research and adjunct appointments. Dr Brown holds a **PhD in Biochemistry and Molecular Biology from Monash University** and is a **Graduate of the Australian Institute of Company Directors**.

Dr Tracey Brown said:

"I lost my mum to ovarian cancer and ever since, I've focused my career on translating science into real options for women and cancer patients. I'm now thrilled to lead GAIASO Theranostics, because our technology has the potential to make a real difference for patients and their families. I'm here to make sure brilliant science becomes accessible care."

Professor Rod Hicks, Chief Medical Officer, commented:

"We are delighted to welcome Tracey as GAIASO's new CEO. Her outstanding track record in leading complex global clinical programmes, combined with her pioneering work in oncology drug development, makes her uniquely placed to guide our company into its next phase. Tracey's vision and passion for improving patient outcomes perfectly align with GAIASO's mission to redefine cancer care."

About GAIASO Theranostics

GAIASO is dedicated to pioneering next-generation precision radiopharmaceuticals for women's cancers. By combining advanced targeting with therapeutic impact, GAIASO is developing innovative solutions designed to transform the way these cancers are diagnosed and treated. With a focus on translating cutting-edge science into accessible care, the company aims to bring new hope and improved outcomes to women affected by cancer worldwide.

For media enquiries, please contact:

Marketing & Communications Team, GAIASO

info@gaiasotheranostics.com

Follow GAIASO on LinkedIn: www.linkedin.com/company/gaiaso-theranostics

Find out more about GAIASO: www.gaiasotheranostics.com